Described herein are compounds of Formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein A, R.sup.1, R.sup.2, R.sup.3, W, X, Y, Z, m, n and p are as defined herein. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.

The present invention relates to substituted macrocyclic indole derivatives of general formula (I):

##STR00001##

in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

A compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of medicaments for treating solid tumor-related diseases. ##STR00001##

A visible light activated ink that produces a color change when exposed to visible light is provided. The ink includes a visible light activated photochromic compound, one or more binders, additives including one or more surfactants, and a solvent. The visible light activated ink is substantially colorless in the as-deposited state and requires a visible light intensity of approximately 300 W/m.sup.2 or greater at a wavelength of approximately 400-700 nm to produce a color change.

A visible light activated ink that produces a color change when exposed to visible light is provided. The ink includes a visible light activated photochromic compound, one or more binders, additives including one or more surfactants, and a solvent. The visible light activated ink is substantially colorless in the as-deposited state and requires a visible light intensity of approximately 300 W/m.sup.2 or greater at a wavelength of approximately 400-700 nm to produce a color change.

The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

##STR00001##

A compound of Formula (I) is provided: (I) where the variables are defined herein.

##STR00001##

A compound of Formula (I) is provided: (I) where the variables are defined herein.

##STR00001##

Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

##STR00001##

Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

##STR00001##